Schizophrenia disorder is a severe and poorly understood mental illness affecting about 1% of the population worldwide. The Swiss psychiatrist, Eugen Bleuler, coined the term schizophrenia (meaning ‘split mind’) in 1911. Despite a high level of heritability, exome sequencing has uncovered only a small percentage of disease-causing protein-coding alterations associated with the aetiology of schizophrenia, which suggests that alternative, presumably gene regulatory, mechanisms may play a major role.

Schizophrenia has historically been investigated using post-mortem tissue and from a drug-induced approach as mouse models incorporating all aspects of the disease have been difficult to establish. Recently, induced pluripotent stem cells have been derived from patients affected with schizophrenia and neurons generated from these cells have begun to uncover molecular mechanisms involved in the disease.

The causes of schizophrenia

The exact cause is unknown.  Stress, genetic factors, harmful alcohol and other drug use, particularly cannabis and amphetamine use, may trigger psychosis in people who are vulnerable to developing schizophrenia.

The symptoms of schizophrenia

The symptoms of schizophrenia fall into three main categories:

  1. Positive: e.g. hallucinations, delusions and thought and movement disorders
  2. Negative: e.g. "Flat affect" (a person's face does not move or he or she talks in a dull or monotonous voice), lack of pleasure in everyday life, lack of the ability to begin and sustain planned activities and speaking little, even when forced to interact.
  3. Cognitive: e.g. Poor executive functioning, trouble focusing or paying attention and problems with working memory.

Options for schizophrenia treatment

Psychotherapy and medications (antipsychotics such as Clozapine, Seroquel, Risperdal or Zyprexa) are most widely used as treatments for schizophrenia .

Garvan's research into schizophrenia

The RNA Biology and Plasticity laboratory is undertaking a significant discovery effort using human patient iPS cells (to derive neuronal cells) and next generation sequencing to investigate the transcriptional landscape dysregulated in schizophrenia-associated neuronal function. This study aims to expose signalling pathways, and the regulation of these, underlying the disease process.

This content is provided for informational purposes only. It is not a substitute for professional medical advice, diagnosis or treatment. If you have any concerns or questions about your health, please consult a suitably qualified healthcare professional.

Key Statistics 

  • 2/3 of people experience their first episode before the age of 25
  • 1.5% of Australians suffer from schizophrenia
  • Schizophrenia incidence is higher in males than females


Please help us continue our breakthrough medical research

Donate Now